Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

INmune Bio Targeting Cancer, Alzheimer's and NASH Simultaneously

We are initiating coverage on INmune Bio Inc. (INMB:NASDAQ) . According to the company, INmune is "Reprogramming the Innate Immune System for the Treatment of Diseases." On the surface, this sounds like a fairly standard biotech tagline, but there's a more here than me...
Streetwise Reports | December 5, 2019 |

Valeo Pharma In-Play, New HesperCo™ Immune System Support Scientifically Demonstrated

Shares of Valeo Pharma Inc. (CSE: VPH) (Frankfurt: VP2) poised for substantial upside revaluation to reflect the major ‘company –maker’ potential in HesperCo™ as the market figures out it is set to be the subject of Covid-19 clinical trial. Valeo will benefit...
Fredrick William | September 2, 2020 |

ChemoCentryx Shares Spike 300% on Phase 3 ANCA Vasculitis Trial Results

Shares of ChemoCentryx Inc. opened greater than 330% higher today after the firm reported positive topline data from its pivotal Phase 3 ADVOCATE trial of Avacopan in treatment of ANCA-associated vasculitis. After the U.S. markets closed yesterday, ChemoCentryx Inc. ...
Streetwise Reports | November 27, 2019 |

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie

Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. Clinical-stage immunotherapy company Alpine Immune S...
Streetwise Reports | June 19, 2020 |

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia

With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. A small-cap Canadian company, Avivagen Inc. (VIV:TSX.V) , has developed a feed supplement, OxC-beta™ Livestock, wh...
Streetwise Reports | November 18, 2019 |

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody. Biotechnology company Curis Inc. (CRIS:NASDAQ) , which concentrates...
Streetwise Reports | June 11, 2020 |

The Golden Bullet for Drug Delivery

It’s the Holy Grail in the cannabis industry. Everyone is trying to innovate the best delivery system to optimize the “bioavailability” (uptake) of medical cannabis in order to offer the perfect pairing -- precise dosing with a fast on...
Marc Davis | January 8, 2020 |

Covid 19: Will pain-free, at-home screening tests be our salvation?

The world’s best defence against the spread of COVID-19 in 2021 will not be a vaccine, medical experts now say. Instead, it will be the widespread adoption of cheap, non-invasive diagnostic detection devices for coronaviruses – ones that look and function...
Marc Davis | September 1, 2020 |

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

Immunotherapy Firm Releases Data Showing Treatment Potential Against Sepsis

Recently presented results from Enlivex Therapeutics' Phase 1b study in sepsis and their implications are reviewed in an H.C. Wainwright & Co. report. In a June 1 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Enlivex Therapeutics Ltd.'s ...
Streetwise Reports | June 4, 2020 |
1 2 3 4 5 6 7 8 9 10 ...